|
First Author
|
Contrast-induced nephropathy*
|
Acetylcysteine Serum Creatinine (μmol/L)
|
Control Serum Creatinine (μmol/L)
|
Dialysis (N)
|
|---|
| |
Acetylcysteine
|
Control
|
Baseline
|
Second SCr
|
Baseline
|
Second SCr
|
NAC
|
Control
|
|---|
|
Allaqaband
25
|
8/45 (18%)
|
6/40 (15%)
|
194.5
|
196.3
|
179.5
|
179.5
|
2
|
0
|
|
Baker
26
|
2/41 (5%)
|
8/39 (21%)
|
163.6
|
156.5
|
154.7
|
159.1
|
0
|
0
|
|
Briguori
27
|
6/92 (7%)
|
10/91 (11%)
|
134.4
|
130.8
|
136.1
|
135.3
|
0
|
1
|
|
Diaz-Sandoval
28
|
2/25 (8%)
|
13/29 (45%)
|
146.7
|
135.5
|
137.9
|
166.2
|
0
|
0
|
|
Durham
29
|
10/38 (26%)
|
9/41 (22%)
|
194.5
|
NR
|
203.3
|
NR
|
NR
|
NR
|
|
Efrati
30
|
0/24 (0%)
|
2/25 (8%)
|
135.3
|
143.2
|
131.7
|
143.2
|
0
|
0
|
|
Fung
31
|
8/46 (17%)
|
6/45 (13%)
|
200.7
|
216.6
|
209.5
|
212.2
|
NR
|
NR
|
|
Goldenberg
32
|
4/41 (10%)
|
3/39 (8%)
|
176.8
|
176.8
|
168.0
|
165.3
|
0
|
0
|
|
Kay
33
|
4/102 (4%)
|
12/98 (12%)
|
119.3
|
107.8
|
120.2
|
122.0
|
0
|
0
|
|
Kefer
34
|
2/53 (8%)
|
3/51 (6%)
|
91.9
|
91.1
|
102.5
|
93.7
|
0
|
0
|
|
MacNeill
35
|
1/21 (5%)
|
7/22 (32%)
|
167.1
|
168.0
|
168.0
|
210.4
|
NR
|
NR
|
|
Oldemeyer
36
|
4/49 (8%)
|
3/47 (6%)
|
144.1
|
NR
|
146.7
|
NR
|
0
|
0
|
|
Shyu
37
|
2/60 (3%)
|
15/61 (25%)
|
247.5
|
221.0
|
247.5
|
274.0
|
0
|
1
|
|
Vallero
38
|
4/47 (9%)
|
4/53 (8%)
|
87.5
|
93.7
|
84
|
86.6
|
NR
|
NR
|
- Legend: SCr = serum creatinine (for conversion to mg/dL divide by 88.4); NR = not recorded or available. *Values are numbers of patients with contrast-induced nephropathy/total number of patients in treatment group (%).
